These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20811704)

  • 1. The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer.
    Morishita A; Gong J; Nomura T; Yoshida H; Izuishi K; Suzuki Y; Kushida Y; Haba R; D'Armiento J; Masaki T
    Int J Oncol; 2010 Oct; 37(4):829-35. PubMed ID: 20811704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
    Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
    Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of protein array to investigate receptor tyrosine kinases activated in gastric cancer.
    Gong J; Morishita A; Kurokohchi K; Tani J; Kato K; Miyoshi H; Inoue H; Kobayashi M; Liu S; Murota M; Muramatsu A; Izuishi K; Suzuki Y; Yoshida H; Uchida N; Deguchi K; Iwama H; Ishimaru I; Masaki T
    Int J Oncol; 2010 Jan; 36(1):101-6. PubMed ID: 19956838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
    Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
    Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.
    Huang J; Wang S; Lyu H; Cai B; Yang X; Wang J; Liu B
    Mol Cancer; 2013 Nov; 12(1):134. PubMed ID: 24215614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
    Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
    Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin synergizes with 5-fluorouracil by impairing AMPK/ULK1-dependent autophagy, AKT activity and enhancing apoptosis in colon cancer cells with tumor growth inhibition in xenograft mice.
    Zhang P; Lai ZL; Chen HF; Zhang M; Wang A; Jia T; Sun WQ; Zhu XM; Chen XF; Zhao Z; Zhang J
    J Exp Clin Cancer Res; 2017 Dec; 36(1):190. PubMed ID: 29273065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation.
    Morii Y; Tsubaki M; Takeda T; Otubo R; Seki S; Yamatomo Y; Imano M; Satou T; Shimomura K; Nishida S
    Eur J Pharmacol; 2021 May; 898():173957. PubMed ID: 33662352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
    D'Alessio A; De Luca A; Maiello MR; Lamura L; Rachiglio AM; Napolitano M; Gallo M; Normanno N
    Breast Cancer Res Treat; 2010 Sep; 123(2):387-96. PubMed ID: 19946741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
    Nakamura Y; Hattori N; Iida N; Yamashita S; Mori A; Kimura K; Yoshino T; Ushijima T
    Cancer Lett; 2017 Aug; 402():100-109. PubMed ID: 28576751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.
    Kennedy SP; Han JZR; Portman N; Nobis M; Hastings JF; Murphy KJ; Latham SL; Cadell AL; Miladinovic D; Marriott GR; O'Donnell YEI; Shearer RF; Williams JT; Munoz AG; Cox TR; Watkins DN; Saunders DN; Timpson P; Lim E; Kolch W; Croucher DR
    Breast Cancer Res; 2019 Mar; 21(1):43. PubMed ID: 30898150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
    Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
    Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment.
    Sun X; Song Q; He L; Yan L; Liu J; Zhang Q; Yu Q
    Mol Cancer Ther; 2016 Oct; 15(10):2508-2520. PubMed ID: 27458140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-κB/iNOS signaling pathways.
    Gao Y; Xiao X; Zhang C; Yu W; Guo W; Zhang Z; Li Z; Feng X; Hao J; Zhang K; Xiao B; Chen M; Huang W; Xiong S; Wu X; Deng W
    J Pineal Res; 2017 Mar; 62(2):. PubMed ID: 27865009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.
    Han S; Meng Y; Tong Q; Li G; Zhang X; Chen Y; Hu S; Zheng L; Tan W; Li H; Chen Y; Zhang G; Li B; Guo Y
    MAbs; 2014; 6(2):403-8. PubMed ID: 24492292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas.
    Zhang Q; Liu JH; Liu JL; Qi CT; Yan L; Chen Y; Yu Q
    BMC Cancer; 2019 Nov; 19(1):1044. PubMed ID: 31690270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
    Shen G; Huang H; Zhang A; Zhao T; Hu S; Cheng L; Liu J; Xiao W; Ling B; Wu Q; Song L; Wei W
    Cancer Immunol Immunother; 2011 Mar; 60(3):339-48. PubMed ID: 21086124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy.
    Zhang YX; van Oosterwijk JG; Sicinska E; Moss S; Remillard SP; van Wezel T; Bühnemann C; Hassan AB; Demetri GD; Bovée JV; Wagner AJ
    Clin Cancer Res; 2013 Jul; 19(14):3796-807. PubMed ID: 23714727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.